Inna Linnik1, Shane McKie2, Jennifer A. Stark3, Simon Luckman3, Bill Deakin2, Steve R. Steve R. Williams1
1Imaging Science and Biomedical Engineering, Manchester University, Manchester, UK; 2Neuroscience and Psychiatry Unit, Manchester University, Manchester, UK; 3Faculty of Life Science, Manchester University, Manchester, UK
Agomelatine is a novel clinically active antidepressant drug. The antidepressant activity of agomelatine needs the combination of melatonin agonist activity and 5-HT2C serotoninergic antagonist properties.